Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices

Dateline City:

WHITEHOUSE STATION, N.J.

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today provided an overview of the clinical trial program for V503, the
company’s investigational 9-valent human papillomavirus (HPV) vaccine,
to the Advisory Committee on Immunization Practices in the United
States. Merck said that the pivotal efficacy trial is complete, the
primary endpoints have been met and the company expects to submit a
Biologics License Application for V503 to the U.S.
Language:

English

Contact:

MerckMedia:Pamela Eisele, [phone]Imraan Munshi, [phone]Investor:Carol Ferguson, [phone]Justin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - October 24, 2013 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news